Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 1998

View Archived Issues

Lilly and Dura collaborate to develop pulmonary delivery of insulin

Dura and Spiros update development of Spiros products

Aviron presents new clinical data for FluMist at ICAAC

Bayer and Novalon enter collaborative agreement to discover antiinfective drugs

NPS Pharmaceuticals initiates clinical trials for NPS-1776

Gene Activated erythropoietin enters phase III clinical trials

Guilford, RPR amend Gliadel marketing and distribution agreement

Major pediatric study supports safety and efficacy of pneumococcal vaccine

Twice-daily Viracept as safe and effective as the approved t.i.d. schedule

Novel erythromycins from HMR useful for Gram-positive and other infections

Piperazines as inhibitors of MMPs and/or TNF-alpha prepared at Fujisawa

BASF patents new series with endothelin-antagonist activity

Neurogen compounds interacting with CRF1 receptors for stress-related disorders

Peptides that bind to MHC class II proteins in development at Zeneca

Selectin inhibitors described by Sanwa Kagaku for inflammatory disorders

Progesterone antagonists claimed for cancer, gynecological disorders by Meiji Seika

Agents for dementia a focus of R&D at Sanofi

ICAAC presentation for potent new anti-HCMV agent from RPR with novel mechanism of action

Japanese investigators design novel class of NMDA receptor channel blocker

Potent, long-acting TxA2 receptor antagonist enters Pfizer development pipeline

Comparative in vitro antipneumococcal activity of CFC-222 presented at ICAAC

MEN-10700 highly active against pneumococci, gonococci and meningococci

Promising new rhinovirus 3C protease inhibitor emerges from Agouron R&D

Results from human pharmacokinetic studies support once-daily dosing for MK-991

Rhone-Poulenc Rorer's CombiPatch now available in the U.S.

Elan invests in Ligand; Ligand obtains certain rights to Morphelan

MC-02479/RWJ-54428: in vitro activity and pharmacokinetics in animals

Fujisawa withdraws NDA for vamicamide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.